nach oben

Erschienen in:

28.02.2020 | Consensus Conference

Consensus statement of the Hellenic and Cypriot Gastric Cancer Study Group on the diagnosis, staging and management of gastric cancer

verfasst von: Gerasimos N. Douridas, Andreas Fountoulakis, John Souglakos, Sofia Gourtsoyianni, Louiza Vini, Georgia Levidou, Theodoros Liakakos, Christos Agalianos, Christos Dervenis, Maria Angeliki Kalogeridi, Ioannis Karavokyros, Anna Koumarianou, Panteleimon Kountourakis, Georgios Oikonomopoulos, Panagiota Economopoulou, Joseph Sgouros, Spiros N. Sgouros, Konstantinos Stamou, Charikleia Triantopoulou, Dimitrios Zacharoulis, Nikolaos Gouvas, Evangelos Xynos

Erschienen in: Updates in Surgery | Ausgabe 1/2020

Einloggen, um Zugang zu erhalten

Abstract

Gastric Cancer epidemics have changed over recent decades, declining in incidence, shifting from distal to proximal location, transforming from intestinal to diffuse histology. Novel chemotherapeutic agents combined with modern surgical operations hardly changed overall disease related survival. This may be attributed to a substantial inherent geographical variation of disease genetics, but also to a failure to standardize and implement treatment protocols in clinical practice. To overcome these drawbacks in Greece and Cyprus, a Gastric Cancer Study Group under the auspices of the Hellenic Society of Medical Oncology (HeSMO) and Gastrointestinal Cancer Study Group (GIC-SG) merged their efforts to produce a consensus considering ethnic parameters of healthcare system and the international proposals as well. Utilizing structured meetings of experts, a consensus was reached. To achieve further consensus, statements were subjected to the Delphi methodology by invited multidisciplinary national and international experts. Sentences were considered of high or low consensus if they were voted by ≥ 80%, or < 80%, respectively; those obtaining a low consensus level after both voting rounds were rejected. Forty-five statements were developed and voted by 71 experts. The median rate of abstention per statement was 9.9% (range: 0–53.5%). At the end of the process, one statement was rejected, another revised, and all the remaining achieved a high consensus. Forty-four recommendations covering all aspects of the management of gastric cancer and concise treatment algorithms are proposed by the Hellenic and Cypriot Gastric Cancer Study Group. The importance of centralization, care by a multidisciplinary team, adherence to guidelines, and individualization are emphasized.

Anderson WF, Camargo MC, Fraumeni JF Jr, Correa P, Rosenberg PS, Rabkin CS (2010) Age-specific trends in incidence of noncardia gastric cancer in US adults. JAMA 303(17):1723–1728. https://doi.org/10.1001/jama.2010.496 CrossRefPubMedPubMedCentral

Powell J, McConkey CC (1990) Increasing incidence of adenocarcinoma of the gastric cardia and adjacent sites. Br J Cancer 62(3):440–443CrossRefPubMedPubMedCentral

Henson DE, Dittus C, Younes M, Nguyen H, Albores-Saavedra J (2004) Differential trends in the intestinal and diffuse types of gastric carcinoma in the United States, 1973–2000: increase in the signet ring cell type. Arch Pathol Lab Med 128(7):765–770. https://doi.org/10.1043/1543-2165(2004)128%3c765:DTITIA%3e2.0.CO;2 CrossRefPubMed

Siegel RL, Miller KD, Jemal A (2019) Cancer statistics. CA Cancer J Clin 69(1):7–34. https://doi.org/10.3322/caac.21551 CrossRefPubMed

Waddell T, Verheij M, Allum W, Cunningham D, Cervantes A, Arnold D et al (2013) Gastric cancer: ESMO-ESSO-ESTRO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 24(Suppl 6):vi57–vi63. https://doi.org/10.1093/annonc/mdt344 CrossRefPubMed

NCCN Clinical Practice Guidelines in Oncology: gastric cancer. Version 4. 2019. https://www.nccn.org/professionals/physician_gls/pdf/gastric.pdf. Accessed date 20 Dec 2019

Patsea E, Kaklamanis L, Batistatou A, Hellenic Society of P (2018) The first report of a 5-year period cancer registry in Greece (2009–2013): a pathology-based cancer registry. Virchows Arch 472(4):677–682. https://doi.org/10.1007/s00428-017-2287-8 CrossRefPubMed

Deaths in Greece, by age and cause (ICD-10) (2015) Hellenic statistical authority. https://www.statistics.gr/el/statistics/-/publication/SPO09/2015. Accessed 23 Aug 2019

New Global Cancer Data: GLOBOCAN 2018. https://gco.iarc.fr. Accessed 30 Aug 2019

10.

Koumarianou A, Krivan S, Machairas N, Ntavatzikos A, Pantazis N, Schizas D et al (2019) Ten-year survival outcomes of patients with potentially resectable gastric cancer: impact of clinicopathologic and treatment-related risk factors. Ann Gastroenterol 32(1):99–106. https://doi.org/10.20524/aog.2018.0320 CrossRefPubMed

11.

Schmoll HJ, Van Cutsem E, Stein A, Valentini V, Glimelius B, Haustermans K et al (2012) ESMO Consensus Guidelines for management of patients with colon and rectal cancer. A personalized approach to clinical decision making. Ann Oncol 23(10):2479–2516. https://doi.org/10.1093/annonc/mds236 CrossRefPubMed

12.

Rowe G, Wright G (1999) The Delphi technique as a forecasting tool: issues and analysis. Int J Forecast 15(4):353–375. https://doi.org/10.1016/s0169-2070(99)00018-7 CrossRef

13.

Serraa O, Galánc M, Ginestab MM, Calvoa M, Salad N, Salazara R (2019) Comparison and applicability of molecular classifications for gastric cancer. Cancer Treat Rev 77:29–34. https://doi.org/10.1016/j.ctrv.2019.05.005 CrossRef

14.

Kaurah P, MacMillan A, Boyd N, Senz J, De Luca A, Chun N et al (2007) Founder and recurrent CDH1 mutations in families with hereditary diffuse gastric cancer. JAMA 297(21):2360–2372. https://doi.org/10.1001/jama.297.21.2360 CrossRefPubMed

15.

Pharoah PD, Guilford P, Caldas C, International Gastric Cancer Linkage C (2001) Incidence of gastric cancer and breast cancer in CDH1 (E-cadherin) mutation carriers from hereditary diffuse gastric cancer families. Gastroenterology 121(6):1348–1353CrossRefPubMed

16.

Fitzgerald RC, Hardwick R, Huntsman D, Carneiro F, Guilford P, Blair V et al (2010) Hereditary diffuse gastric cancer: updated consensus guidelines for clinical management and directions for future research. J Med Genet 47(7):436–444. https://doi.org/10.1136/jmg.2009.074237 CrossRefPubMed

17.

Norton JA, Ham CM, Van Dam J, Jeffrey RB, Longacre TA, Huntsman DG et al (2007) CDH1 truncating mutations in the E-cadherin gene: an indication for total gastrectomy to treat hereditary diffuse gastric cancer. Ann Surg 245(6):873–879. https://doi.org/10.1097/01.sla.0000254370.29893.e4 CrossRefPubMedPubMedCentral

18.

Kluijt I, Sijmons RH, Hoogerbrugge N, Plukker JT, de Jong D, van Krieken JH et al (2012) Familial gastric cancer: guidelines for diagnosis, treatment and periodic surveillance. Fam Cancer 11(3):363–369. https://doi.org/10.1007/s10689-012-9521-y CrossRefPubMed

19.

Shenoy S (2019) CDH1 (E-Cadherin) mutation and gastric cancer: Genetics, molecular mechanisms and guidelines for management. Cancer Manag Res 13(11):10477–10486. https://doi.org/10.2147/CMAR.S208818 CrossRef

20.

Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A et al (2010) Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 376(9742):687–697. https://doi.org/10.1016/S0140-6736(10)61121-X CrossRefPubMed

21.

Lei YY, Huang JY, Zhao QR, Jiang N, Xu HM, Wang ZN et al (2017) The clinicopathological parameters and prognostic significance of HER2 expression in gastric cancer patients: a meta-analysis of literature. World J Surg Oncol 15(1):68. https://doi.org/10.1186/s12957-017-1132-5 CrossRefPubMedPubMedCentral

22.

Sohn BH, Hwang JE, Jang HJ, Lee HS, Oh SC, Shim JJ et al (2017) Clinical significance of four molecular subtypes of gastric cancer identified by the cancer genome atlas project. Clin Cancer Res 1(23):4441–4449. https://doi.org/10.1158/1078-0432.CCR-16-2211 CrossRef

23.

Le DT, Uram JN, Wang H, Bartlett BR, Kemberling H, Eyring AD et al (2015) PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med 372(26):2509–2520. https://doi.org/10.1056/NEJMoa1500596 CrossRefPubMedPubMedCentral

24.

Hu B, El Hajj N, Sittler S, Lammert N, Barnes R, Meloni-Ehrig A (2012) Gastric cancer: classification, histology and application of molecular pathology. J Gastrointest Oncol 3(3):251–261. https://doi.org/10.3978/j.issn.2078-6891.2012.021 CrossRefPubMedPubMedCentral

25.

Lauren P (1965) The two histological main types of gastric carcinoma: diffuse and so-called intestinal-type carcinoma. An attempt at a histo-clinical classification. Acta pathologica et microbiologica Scandinavica 64:31–49CrossRefPubMed

26.

WHO classification of tumours, 5th Edition, Volume 1. Digestive System Tumors. ISBN-139789283244998 IARC Publications. https://apps.who.int/bookorders/anglais/detart1.jsp?codlan=1&codcol=70&codcch=24003. Accessed 30 Aug 2019

27.

Talley NJ, Vakil N, Practice Parameters Committee of the American College of G (2005) Guidelines for the management of dyspepsia. Am J Gastroenterol 100(10):2324–2337. https://doi.org/10.1111/j.1572-0241.2005.00225.x CrossRefPubMed

28.

Kwack WG, Ho WJ, Kim JH, Lee JH, Kim EJ, Kang HW, Lee JK (2016) Understanding the diagnostic yield of current endoscopic biopsy for gastric neoplasm. Medicine 95(30):e4196. https://doi.org/10.1097/md.0000000000004196 CrossRefPubMedPubMedCentral

29.

Bentrem D, Gerdes H, Tang L, Brennan M, Coit D (2007) Clinical correlation of endoscopic ultrasonography with pathologic stage and outcome in patients undergoing curative resection for gastric cancer. Ann Surg Oncol 14(6):1853–1859. https://doi.org/10.1245/s10434-006-9037-5 CrossRefPubMed

30.

Botet JF, Lightdale CJ, Zauber AG, Gerdes H, Winawer SJ, Urmacher C et al (1991) Preoperative staging of gastric cancer: comparison of endoscopic US and dynamic CT. Radiology 181(2):426–432. https://doi.org/10.1148/radiology.181.2.1924784 CrossRefPubMed

31.

Okada K, Fujisaki J, Kasuga A, Omae M, Yoshimoto K, Hirasawa T et al (2011) Endoscopic ultrasonography is valuable for identifying early gastric cancers meeting expanded-indication criteria for endoscopic submucosal dissection. Surg Endosc 25(3):841–848. https://doi.org/10.1007/s00464-010-1279-4 CrossRefPubMed

32.

Karita M, Tada M (1994) Endoscopic and histologic diagnosis of submucosal tumors of the gastrointestinal tract using combined strip biopsy and bite biopsy. Gastrointest Endosc 40(6):749–753CrossRefPubMed

33.

Yahagi N, Fujishiro M, Kakushima N, Kobayashi K, Hashimoto T, Oka M et al (2004) Endoscopic submucosal dissection for early gastric cancer using the tip of an electrosurgical snare (thin type). Dig Endosc 16:34–38. https://doi.org/10.1111/j.1443-1661.2004.00313.x CrossRef

34.

Lee IJ, Lee JM, Kim SH, Shin CI, Lee JY, Kim SH et al (2010) Diagnostic performance of 64-channel multidetector CT in the evaluation of gastric cancer: differentiation of mucosal cancer (T1a) from submucosal involvement (T1b and T2). Radiology 255(3):805–814. https://doi.org/10.1148/radiol.10091313 CrossRefPubMed

35.

Nagpal P, Prakash A, Pradhan G, Vidholia A, Nagpal N, Saboo SS et al (2017) MDCT imaging of the stomach: advances and applications. Br J Radiol 90(1069):20160412. https://doi.org/10.1259/bjr.20160412 CrossRefPubMed

36.

Monig SP, Zirbes TK, Schroder W, Baldus SE, Lindemann DG, Dienes HP et al (1999) Staging of gastric cancer: correlation of lymph node size and metastatic infiltration. AJR Am J Roentgenol 173(2):365–367. https://doi.org/10.2214/ajr.173.2.10430138 CrossRefPubMed

37.

Liu S, Zhang Y, Chen L, Guan W, Guan Y, Ge Y et al (2017) Whole-lesion apparent diffusion coefficient histogram analysis: significance in T and N staging of gastric cancers. BMC Cancer 17(1):665. https://doi.org/10.1186/s12885-017-3622-9 CrossRefPubMedPubMedCentral

38.

Allen CJ, Newhook TE, Vreeland TJ, Das P, Minsky BD, Blum M et al (2019) Yield of peritoneal cytology in staging patients with gastric and gastroesophageal cancer. J Surg Oncol 120:1350–1357. https://doi.org/10.1002/jso25729 CrossRefPubMed

39.

Chang L, Stefanidis D, Richardson WS, Earle DB, Fanelli RD (2009) The role of staging laparoscopy for intraabdominal cancers: an evidence-based review. Surg Endosc 23(2):231–241. https://doi.org/10.1007/s00464-008-0099-2 (Published online 2008 Sep 24)CrossRefPubMed

40.

Smyth EC, Verheij M, Allum W, Cunningham D, Cervantes A, Arnold D (2016) ESMO guidelines committee. Ann Oncol 27(suppl 5):v38–v49. https://doi.org/10.1093/annonc/mdw350 CrossRefPubMed

41.

Seevaratnam R, Cardoso R, McGregor C, Lourenco L, Mahar A, Sutradhar R et al (2012) How useful is preoperative imaging for tumor, node, metastasis (TNM) staging of gastric cancer? A meta-analysis. Gastric Cancer 15(Suppl 1):S3–18. https://doi.org/10.1007/s10120-011-0069-6 (Published online 2011 Aug 12)CrossRefPubMed

42.

Fukagawa T (2019) Role of staging laparoscopy for gastric cancer patients. Ann Gastroenterol Surg 3(5):496–505. https://doi.org/10.1002/ags3.12283 CrossRefPubMedPubMedCentral

43.

Bollschweiler E, Berlth F, Baltin C, Monig S, Holscher AH (2014) Treatment of early gastric cancer in the Western World. World J Gastroenterol 20(19):5672–5678. https://doi.org/10.3748/wjg.v20.i19.5672 CrossRefPubMedPubMedCentral

44.

Oda I, Saito D, Tada M, Iishi H, Tanabe S, Oyama T et al (2006) A multicenter retrospective study of endoscopic resection for early gastric cancer. Gastric Cancer 9:262. https://doi.org/10.1007/s10120-006-0389-0 CrossRefPubMed

45.

Cao Y, Liao C, Tan A, Gao Y, Mo Z, Gao F (2009) Meta-analysis of endoscopic submucosal dissection versus endoscopic mucosal resection for tumors of the gastrointestinal tract. Endoscopy 41(9):751–757. https://doi.org/10.1055/s-0029-1215053 CrossRefPubMed

46.

Hoteya S, Iizuka T, Kikuchi D, Yahagi N (2009) Benefits of endoscopic submucosal dissection according to size and location of gastric neoplasm, compared with conventional mucosal resection. J Gastroenterol Hepatol 24(6):1102–1106. https://doi.org/10.1111/j.1440-1746.2009.05811.x CrossRefPubMed

47.

Nakamoto S, Sakai Y, Kasanuki J, Kondo F, Ooka Y, Kato K et al (2009) Indications for the use of endoscopic mucosal resection for early gastric cancer in Japan: a comparative study with endoscopic submucosal dissection. Endoscopy 41(9):746–750. https://doi.org/10.1055/s-0029-1215010 CrossRefPubMed

48.

Watanabe T, Kume K, Taip M, Shibata M, Kubo H, Ejiri Y et al (2010) Gastric mucosal cancer smaller than 7mm can be treated with conventional endoscopic mucosal resection as effectively as with endoscopic submucosal dissection. Hepatogastroenterology 57(99–100):668–673PubMed

49.

Cunningham D, Allum WH, Stenning SP, Thompson JN, Van de Velde CJ, Nicolson M et al (2006) Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med 355(1):11–20. https://doi.org/10.1056/NEJMoa055531 CrossRefPubMed

50.

Ychou M, Boige V, Pignon JP, Conroy T, Bouche O, Lebreton G et al (2011) Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial. J Clin Oncol 29(13):1715–1721. https://doi.org/10.1200/JCO.2010.33.0597 CrossRefPubMed

51.

Reddavid R, Sofia S, Chiaro P, Colli F, Trapani R, Esposito L et al (2018) Neoadjuvant chemotherapy for gastric cancer. Is it a must or a fake? World J Gastroenterol 24(2):274–289. https://doi.org/10.3748/wjg.v24.i2.274 CrossRefPubMedPubMedCentral

52.

Al-Batran SE, Homann N, Pauligk C, Goetze TO, Meiler J, Kasper S et al (2019) Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial. Lancet 393(10184):1948–1957. https://doi.org/10.1016/S0140-6736(18)32557-1 CrossRefPubMed

53.

Macdonald JS, Smalley SR, Benedetti J, Hundahl SA, Estes NC, Stemmermann GN et al (2001) Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med 345(10):725–730. https://doi.org/10.1056/NEJMoa010187 CrossRefPubMed

54.

Smalley SR, Benedetti JK, Haller DG, Hundahl SA, Estes NC, Ajani JA et al (2012) Updated analysis of SWOG-directed intergroup study 0116: a phase III trial of adjuvant radiochemotherapy versus observation after curative gastric cancer resection. J Clin Oncol 30(19):2327–2333. https://doi.org/10.1200/JCO.2011.36.7136 CrossRefPubMedPubMedCentral

55.

Noh SH, Park SR, Yang HK, Chung HC, Chung IJ, Kim SW et al (2014) Adjuvant capecitabine plus oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): 5-year follow-up of an open-label, randomised phase 3 trial. Lancet Oncol 15(12):1389–1396. https://doi.org/10.1016/S1470-2045(14)70473-5 CrossRefPubMed

56.

Sasako M, Sakuramoto S, Katai H, Kinoshita T, Furukawa H, Yamaguchi T et al (2011) Five-year outcomes of a randomized phase III trial comparing adjuvant chemotherapy with S-1 versus surgery alone in stage II or III gastric cancer. J Clin Oncol 29(33):4387–4393. https://doi.org/10.1200/JCO.2011.36.5908 CrossRefPubMed

57.

Makino T, Fujiwara Y, Takiguchi S, Tsuboyama T, Kim T, Nushijima Y et al (2011) Preoperative T staging of gastric cancer by multi-detector row computed tomography. Surgery 149(5):672–679. https://doi.org/10.1016/j.surg.2010.12.003 CrossRefPubMed

58.

Morgagni P, Solaini L, Framarini M, Vittimberga G, Gardini A, Tringali D, Valgiusti M, Monti M, Ercolani G (2018) Conversion surgery for gastric cancer: a cohort study from a western center. Int J Surg 53:360–365. https://doi.org/10.1016/j.ijsu.2018.04.016 CrossRefPubMed

59.

Zurleni T, Gjoni E, Altomare M, Rausei S (2018) Conversion surgery for gastric cancer patients: a review. World J Gastrointest Oncol 10(11):398–409. https://doi.org/10.4251/wjgo.v10.i11.398 CrossRefPubMedPubMedCentral

60.

Ajani JA, Winter K, Okawara GS, Donohue JH, Pisters PW, Crane CH et al (2006) Phase II trial of preoperative chemoradiation in patients with localized gastric adenocarcinoma (RTOG 9904): quality of combined modality therapy and pathologic response. J Clin Oncol 24(24):3953–3958. https://doi.org/10.1200/JCO.2006.06.4840 CrossRefPubMed

61.

Leong T, Smithers BM, Haustermans K, Michael M, Gebski V, Miller D et al (2017) TOPGEAR: a randomized, phase III trial of perioperative ECF chemotherapy with or without preoperative chemoradiation for resectable gastric cancer: interim results from an international, intergroup trial of the AGITG, TROG, EORTC and CCTG. Ann Surg Oncol 24(8):2252–2258. https://doi.org/10.1245/s10434-017-5830-6 CrossRefPubMed

62.

Songun I, Putter H, Kranenbarg EM, Sasako M, van de Velde CJ (2010) Surgical treatment of gastric cancer: 15-year follow-up results of the randomised nationwide Dutch D1D2 trial. Lancet Oncol 11(5):439–449. https://doi.org/10.1016/S1470-2045(10)70070-X CrossRefPubMed

63.

Postlewait LM, Maithel SK (2016) The importance of surgical margins in gastric cancer. J Surg Oncol 113(3):277–282. https://doi.org/10.1002/jso.24110 CrossRefPubMed

64.

Yu W, Choi GS, Chung HY (2006) Randomized clinical trial of splenectomy versus splenic preservation in patients with proximal gastric cancer. Br J Surg 93(5):559–563. https://doi.org/10.1002/bjs.5353 CrossRefPubMed

65.

Sano T, Sasako M, Mizusawa J, Yamamoto S, Katai H, Yoshikawa T et al (2017) Randomized controlled trial to evaluate splenectomy in total gastrectomy for proximal gastric carcinoma. Ann Surg 265(2):277–283. https://doi.org/10.1097/SLA.0000000000001814 CrossRefPubMed

66.

Jongerius EJ, Boerma D, Seldenrijk KA, Meijer SL, Scheepers JJG, Smedts F et al (2016) Role of omentectomy as part of radical surgery for gastric cancer. Br J Surg 103:1497–1503. https://doi.org/10.1002/bjs.10149 CrossRefPubMed

67.

Haverkamp L, Brenkman HJ, Ruurda JP, Ten Kate FJ, van Hillegersberg R (2016) The oncological value of omentectomy in gastrectomy for cancer. J Gastrointest Surg 20(5):885–890. https://doi.org/10.1007/s11605-016-3092-4 CrossRefPubMedPubMedCentral

68.

Hirao M, Kurokawa Y, Fujita J et al (2015) Long-term outcomes after prophylactic bursectomy in patients with resectable gastric cancer: final analysis of a multicenter randomized controlled trial. Surgery 157:1099–1105CrossRefPubMed

69.

Marano L, Polom K, Bartoli A, Spaziani A, De Luca R, Lorenzon L et al (2018) Oncologic effectiveness and safety of bursectomy in patients with advanced gastric cancer: a systematic review and updated meta-analysis. J Invest Surg 31(6):529–538. https://doi.org/10.1080/08941939.2017.1355942 CrossRefPubMed

70.

Kurokawa Y, Doki Y, Mizusawa J, Terashima M, Katai H, Yoshikawa T et al (2018) Bursectomy versus omentectomy alone for resectable gastric cancer (JCOG1001): a phase 3, open-label, randomised controlled trial. Lancet Gastroenterol Hepatol 3(7):460–468. https://doi.org/10.1016/S2468-1253(18)30090-6 CrossRefPubMed

71.

Lee MS, Ahn SH, Lee JH, Park DJ, Lee HJ, Kim HH et al (2012) What is the best reconstruction method after distal gastrectomy for gastric cancer? Surg Endosc 26(6):1539–1547. https://doi.org/10.1007/s00464-011-2064-8 CrossRefPubMed

72.

Hirao M, Takiguchi S, Imamura H, Yamamoto K, Kurokawa Y, Fujita J et al (2013) Comparison of Billroth I and Roux-en-Y reconstruction after distal gastrectomy for gastric cancer: one-year postoperative effects assessed by a multi-institutional RCT. Ann Surg Oncol 20(5):1591–1597. https://doi.org/10.1245/s10434-012-2704-9 CrossRefPubMed

73.

Gertler R, Rosenberg R, Feith M, Schuster T, Friess H (2009) Pouch vs. no pouch following total gastrectomy: meta-analysis and systematic review. Am J Gastroenterol 104(11):2838–2851. https://doi.org/10.1038/ajg.2009.456 CrossRefPubMed

74.

Kim HH, Han SU, Kim MC, Kim W, Lee HJ, Ryu SW et al (2019) Effect of laparoscopic distal gastrectomy vs open distal gastrectomy on long-term survival among patients with stage I gastric cancer: the KLASS-01 randomized clinical trial. JAMA Oncol 5(4):506–513. https://doi.org/10.1001/jamaoncol.2018.6727 CrossRefPubMedPubMedCentral

75.

Thomassen I, van Gestel YR, van Ramshorst B, Luyer MD, Bosscha K, Nienhuijs SW et al (2014) Peritoneal carcinomatosis of gastric origin: a population-based study on incidence, survival and risk factors. Int J Cancer 134(3):622–628. https://doi.org/10.1002/ijc.28373 CrossRefPubMed

76.

Brenkman HJF, Päeva M, van Hillegersberg R, Ruurda JP, Haj MN (2019) Prophylactic hyperthermic intraperitoneal chemotherapy (HIPEC) for gastric cancer-a systematic review. J Clin Med 8(10):1685. https://doi.org/10.3390/jcm8101685 CrossRefPubMedCentral

77.

Jansen EP, Boot H, Saunders MP, Crosby TD, Dubbelman R, Bartelink H et al (2007) A phase I-II study of postoperative capecitabine-based chemoradiotherapy in gastric cancer. Int J Radiat Oncol Biol Phys 69(5):1424–1428. https://doi.org/10.1016/j.ijrobp.2007.05.004 CrossRefPubMed

78.

Tham CK, Choo SP, Poon DY, Toh HC, Ong SY, Tan SH et al (2010) Capecitabine with radiation is an effective adjuvant therapy in gastric cancers. World J Gastroenterol 16(29):3709–3715CrossRefPubMedPubMedCentral

79.

Zhou ML, Kang M, Li GC, Guo XM, Zhang Z (2016) Postoperative chemoradiotherapy versus chemotherapy for R0 resected gastric cancer with D2 lymph node dissection: an up-to-date meta-analysis. World J Surg Oncol 14(1):209. https://doi.org/10.1186/s12957-016-0957-7 CrossRefPubMedPubMedCentral

80.

Fuchs CS, Niedzwiecki D, Mamon HJ, Tepper JE, Ye X, Swanson RS et al (2017) Adjuvant chemoradiotherapy With epirubicin, cisplatin, and fluorouracil compared with adjuvant chemoradiotherapy with fluorouracil and leucovorin after curative resection of gastric cancer: results from CALGB 80101 (Alliance). J Clin Oncol 35(32):3671–3677. https://doi.org/10.1200/JCO.2017.74.2130 CrossRefPubMedPubMedCentral

81.

Cats A, Jansen EPM, van Grieken NCT, Sikorska K, Lind P, Nordsmark M et al (2018) Chemotherapy versus chemoradiotherapy after surgery and preoperative chemotherapy for resectable gastric cancer (CRITICS): an international, open-label, randomised phase 3 trial. Lancet Oncol 19(5):616–628. https://doi.org/10.1016/S1470-2045(18)30132-3 CrossRefPubMed

82.

Lee J, Lim DH, Kim S, Park SH, Park JO, Park YS et al (2012) Phase III trial comparing capecitabine plus cisplatin versus capecitabine plus cisplatin with concurrent capecitabine radiotherapy in completely resected gastric cancer with D2 lymph node dissection: the ARTIST trial. J Clin Oncol 30(3):268–273. https://doi.org/10.1200/JCO.2011.39.1953 CrossRefPubMed

83.

Park SH, Sohn TS, Lee J, Lim DH, Hong ME, Kim KM et al (2015) Phase III trial to compare adjuvant chemotherapy with capecitabine and cisplatin versus concurrent chemoradiotherapy in gastric cancer: final report of the adjuvant chemoradiotherapy in stomach tumors trial, including survival and subset analyses. J Clin Oncol 33(28):3130–3136. https://doi.org/10.1200/JCO.2014.58.3930 CrossRefPubMed

84.

Dikken JL, Jansen EP, Cats A, Bakker B, Hartgrink HH, Kranenbarg EM et al (2010) Impact of the extent of surgery and postoperative chemoradiotherapy on recurrence patterns in gastric cancer. J Clin Oncol 28(14):2430–2436. https://doi.org/10.1200/JCO.2009.26.9654 CrossRefPubMed

85.

Liu TS, Wang Y, Chen SY, Sun YH (2008) An updated meta-analysis of adjuvant chemotherapy after curative resection for gastric cancer. Eur J Surg Oncol 34(11):1208–1216. https://doi.org/10.1016/j.ejso.2008.02.002 CrossRefPubMed

86.

Paoletti X, Oba K, Burzykowski T, Michiels S, Ohashi Y, Pignon JP et al (2010) Benefit of adjuvant chemotherapy for resectable gastric cancer: a meta-analysis. JAMA 303(17):1729–1737. https://doi.org/10.1001/jama.2010.534 CrossRefPubMed

87.

Bang YJ, Kim YW, Yang HK, Chung HC, Park YK, Lee KH et al (2012) Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial. Lancet 379(9813):315–321. https://doi.org/10.1016/S0140-6736(11)61873-4 CrossRefPubMed

88.

O’Sullivan BBJ, D’Cruz AK et al (2015) UICC manual of clinical oncology. Wiley, HobokenCrossRef

89.

Baiocchi GL, D’Ugo D, Coit D et al (2016) Follow-up after gastrectomy for cancer: the Charter Scaligero Consensus Conference. Gastric Cancer 19:15–20. https://doi.org/10.1007/s10120-015-0513-0 CrossRefPubMed

90.

Nilsson M (2017) Postgastrectomy follow-up in the West: evidence base, guidelines, and daily practice. Gastric Cancer 20(Suppl 1):135–140. https://doi.org/10.1007/s10120-016-0654-9 CrossRefPubMed

91.

Casaretto L, Sousa PLR, Mari JJ (2006) Chemotherapy versus support cancer treatment in advanced gastric cancer: a meta-analysis. Braz J Med Biol Res [Internet]. 39(4):431–440. https://www.scielo.br/scielo.php?script=sci_arttext&pid=S0100-879X2006000400002&lng=en. https://dx.doi.org/10.1590/S0100-879X2006000400002

92.

Cunningham D, Starling N, Rao S, Iveson T, Nicolson M, Coxon F et al (2008) Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med 358(1):36–46. https://doi.org/10.1056/NEJMoa073149 CrossRefPubMed

93.

Van Cutsem E, Moiseyenko VM, Tjulandin S, Majlis A, Constenla M, Boni C et al (2006) Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group. J Clin Oncol 24(31):4991–4997. https://doi.org/10.1200/JCO.2006.06.8429 CrossRefPubMed

94.

Guimbaud R, Louvet C, Ries P, Ychou M, Maillard E, Andre T et al (2014) Prospective, randomized, multicenter, phase III study of fluorouracil, leucovorin, and irinotecan versus epirubicin, cisplatin, and capecitabine in advanced gastric adenocarcinoma: a French intergroup (Federation Francophone de Cancerologie Digestive, Federation Nationale des Centres de Lutte Contre le Cancer, and Groupe Cooperateur Multidisciplinaire en Oncologie) study. J Clin Oncol 32(31):3520–3526. https://doi.org/10.1200/JCO.2013.54.1011 CrossRefPubMed

95.

Thuss-Patience PC, Kretzschmar A, Bichev D, Deist T, Hinke A, Breithaupt K et al (2011) Survival advantage for irinotecan versus best supportive care as second-line chemotherapy in gastric cancer–a randomised phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO). Eur J Cancer 47(15):2306–2314. https://doi.org/10.1016/j.ejca.2011.06.002 CrossRefPubMed

96.

Hironaka S, Ueda S, Yasui H, Nishina T, Tsuda M, Tsumura T et al (2013) Randomized, open-label, phase III study comparing irinotecan with paclitaxel in patients with advanced gastric cancer without severe peritoneal metastasis after failure of prior combination chemotherapy using fluoropyrimidine plus platinum: WJOG 4007 trial. J Clin Oncol 31(35):4438–4444. https://doi.org/10.1200/JCO.2012.48.5805 CrossRefPubMed

97.

Wilke H, Muro K, Van Cutsem E, Oh SC, Bodoky G, Shimada Y et al (2014) Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial. Lancet Oncol 15(11):1224–1235. https://doi.org/10.1016/S1470-2045(14)70420-6 CrossRefPubMed

98.

Fuchs CS, Tomasek J, Yong CJ, Dumitru F, Passalacqua R, Goswami C et al (2014) Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet 383(9911):31–39. https://doi.org/10.1016/S0140-6736(13)61719-5 CrossRefPubMed

99.

Le DT, Durham JN, Smith KN, Wang H, Bartlett BR, Aulakh LK et al (2017) Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. Science 357(6349):409–413. https://doi.org/10.1126/science.aan6733 CrossRefPubMedPubMedCentral

100.

Cancer Genome Atlas Research N (2014) Comprehensive molecular characterization of gastric adenocarcinoma. Nature 513(7517):202–209. https://doi.org/10.1038/nature13480 CrossRef

101.

Asakura H, Hashimoto T, Harada H, Mizumoto M, Furutani K, Hasuike N et al (2011) Palliative radiotherapy for bleeding from advanced gastric cancer: is a schedule of 30 Gy in 10 fractions adequate? J Cancer Res Clin Oncol 137(1):125–130. https://doi.org/10.1007/s00432-010-0866-z CrossRefPubMed

102.

Kondoh C, Shitara K, Nomura M, Takahari D, Ura T, Tachibana H et al (2015) Efficacy of palliative radiotherapy for gastric bleeding in patients with unresectable advanced gastric cancer: a retrospective cohort study. BMC Palliative Care 14:37. https://doi.org/10.1186/s12904-015-0034-y CrossRefPubMedPubMedCentral

103.

Tey J, Soon YY, Koh WY, Leong CN, Choo BA, Ho F et al (2017) Palliative radiotherapy for gastric cancer: a systematic review and meta-analysis. Oncotarget 8(15):25797–25805. https://doi.org/10.18632/oncotarget.15554 CrossRefPubMedPubMedCentral

Titel: Consensus statement of the Hellenic and Cypriot Gastric Cancer Study Group on the diagnosis, staging and management of gastric cancer
verfasst von: Gerasimos N. Douridas
Andreas Fountoulakis
John Souglakos
Sofia Gourtsoyianni
Louiza Vini
Georgia Levidou
Theodoros Liakakos
Christos Agalianos
Christos Dervenis
Maria Angeliki Kalogeridi
Ioannis Karavokyros
Anna Koumarianou
Panteleimon Kountourakis
Georgios Oikonomopoulos
Panagiota Economopoulou
Joseph Sgouros
Spiros N. Sgouros
Konstantinos Stamou
Charikleia Triantopoulou
Dimitrios Zacharoulis
Nikolaos Gouvas
Evangelos Xynos
Publikationsdatum: 28.02.2020
Verlag: Springer International Publishing
Erschienen in: Updates in Surgery / Ausgabe 1/2020
Print ISSN: 2038-131X
Elektronische ISSN: 2038-3312
DOI: https://doi.org/10.1007/s13304-020-00723-8

Neu im Fachgebiet Chirurgie

23.04.2024 | Ablationstherapie | Nachrichten

Wie erfolgreich ist eine Re-Ablation nach Rezidiv?

23.04.2024 | Appendizitis | Nachrichten

Hinter dieser Appendizitis steckte ein Erreger

23.04.2024 | Operationsvorbereitung | Nachrichten

Mehr Schaden als Nutzen durch präoperatives Aussetzen von GLP-1-Agonisten?

19.04.2024 | EAU 2024 | Kongressbericht | Nachrichten

Ureterstriktur: Innovative OP-Technik bewährt sich

weitere anzeigen

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Aktuelle BDC Leitlinien-Webinare

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

Karpaltunnelsyndrom BDC Leitlinien Webinare

CME: 2 Punkte

Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis

S2e-Leitlinie „Distale Radiusfraktur“

Radiusfraktur BDC Leitlinien Webinare

CME: 2 Punkte

Das Webinar beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske

Dr. med. Benjamin Meyknecht

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

Appendizitis BDC Leitlinien Webinare

CME: 2 Punkte

Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2020

Is follow-up still mandatory more than 5 years after surgery for colorectal cancer?

Retrograde tracing along “cystic duct” method to prevent biliary misidentification injury in laparoscopic cholecystectomy

Colorectal cancer-screening program improves both short- and long-term outcomes: a single-center experience in Trieste

Laparoscopy and resection with primary anastomosis for perforated diverticulitis: challenging old dogmas

Fallopian tubal obstruction is associated with increased pain experienced during office hysteroscopy: a retrospective study

Short-term outcome of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy used as treatment of colo-rectal carcinomatosis: a multicentric study

Neu im Fachgebiet Chirurgie

Wie erfolgreich ist eine Re-Ablation nach Rezidiv?

Hinter dieser Appendizitis steckte ein Erreger

Mehr Schaden als Nutzen durch präoperatives Aussetzen von GLP-1-Agonisten?

Ureterstriktur: Innovative OP-Technik bewährt sich

Update Chirurgie

Aktuelle BDC Leitlinien-Webinare

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

S2e-Leitlinie „Distale Radiusfraktur“

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“